Reaction

Hormone Level Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,747 reports · 95 co-occurring drugs

As of the last recalculation, Hormone Level Abnormal appears in 4,747 FAERS reports alongside 95 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 21.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Octreotide Acetate	143	21.1	21.2
Progesterone	82	16.0	16.0
Finasteride	209	15.8	15.9
Estradiol	264	14.1	14.2
Lanreotide Acetate	23	12.9	13.0
Etonogestrel	120	11.3	11.3
Estradiol Gel 0.1%	108	10.7	10.7
Estradiol Transdermal	108	10.7	10.7
Etonogestrel And Ethinyl Estradiol	45	9.0	9.0
Thyroid, Porcine	21	8.7	8.7
Levonorgestrel	356	8.3	8.3
Conjugated Estrogens	99	7.6	7.6
Estrogens, Conjugated	100	7.5	7.5
Medroxyprogesterone Acetate	84	7.5	7.5
Elexacaftor, Tezacaftor, And Ivacaftor	21	7.4	7.4
Testosterone	39	7.4	7.4
Goserelin	22	7.2	7.2
Liothyronine Sodium	13	6.6	6.6
Testosterone Cypionate	13	6.4	6.4
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	48	6.0	6.0
Conjugated Estrogens And Medroxyprogesterone Acetate	32	6.0	6.0
Cyclobenzaprine Hydrochloride	12	5.9	5.9
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	52	5.5	5.6
Sodium Oxybate	77	5.2	5.2
Drospirenone And Ethinyl Estradiol	47	4.7	4.7
Somatropin	77	4.7	4.7
Naltrexone Hydrochloride And Bupropion Hydrochloride	9	4.6	4.6
Calcium, Magnesium, Potassium, And Sodium Oxybates	9	4.6	4.6
Relugolix	23	4.3	4.3
Copper	41	4.2	4.2
Biotin	29	4.1	4.1
Rizatriptan Benzoate	9	3.9	3.9
Leuprolide Acetate	66	3.8	3.8
Anastrozole	31	3.7	3.7
Armodafinil	17	3.5	3.5
Ribociclib	25	3.5	3.5
Sumatriptan Succinate	20	3.5	3.5
Lisdexamfetamine Dimesylate	26	3.5	3.5
Doxepin	8	3.5	3.5
Carisoprodol	15	3.5	3.5
Fremanezumab-Vfrm	9	3.4	3.4
Fulvestrant	25	3.3	3.3
Anastrozole Tablets	16	3.3	3.3
Tretinoin	6	3.2	3.2
Orlistat	19	3.2	3.2
Letrozole	44	3.2	3.2
Asfotase Alfa	7	3.1	3.1
Ketoconazole	12	3.0	3.0
Chlorthalidone	8	3.0	3.0
Alpelisib	6	3.0	3.0
Galcanezumab-Gnlm	21	2.9	2.9
Letrozole Tablets	32	2.9	2.9
Dolutegravir Sodium	6	2.9	2.9
Buprenorphine Hydrochloride, Naloxone Hydrochloride	16	2.9	2.9
Exemestane	14	2.9	2.9
Prochlorperazine Maleate	6	2.9	2.9
Rimegepant Sulfate	8	2.8	2.8
Divalproex Sodium	29	2.7	2.7
Oxazepam	13	2.7	2.7
Desvenlafaxine Succinate	16	2.6	2.6
Modafinil	19	2.6	2.6
Olanzapine Pamoate	24	2.6	2.6
Lumacaftor And Ivacaftor	5	2.6	2.6
Ziprasidone Mesylate	8	2.5	2.5
Paliperidone Palmitate	17	2.3	2.3
Desoximetasone	10	2.3	2.3
Risperidone	69	2.3	2.3
Apalutamide	6	2.2	2.2
Loratadine And Pseudoephedrine Sulfate	4	2.2	2.2
Vilazodone Hydrochloride	4	1.9	1.9
Paliperidone	10	1.9	1.9
Cannabidiol	10	1.9	1.9
Atomoxetine Hydrochloride	10	1.8	1.8
Bimekizumab	8	1.6	1.6
Hydrocodone Bitartrate And Acetaminophen	21	1.6	1.6
Emtricitabine And Tenofovir Alafenamide	4	1.5	1.5
Voclosporin	3	1.5	1.5
Brivaracetam	3	1.5	1.5
Avapritinib	4	1.4	1.4
Eptinezumab-Jjmr	3	1.4	1.4
Erenumab-Aooe	18	1.4	1.4
Palbociclib	30	1.4	1.4
Suvorexant	4	1.4	1.4
Dornase Alfa	6	1.3	1.3
Ofatumumab	10	1.3	1.3
Isotretinoin	14	1.2	1.2
Onabotulinumtoxina	21	1.2	1.2
Abemaciclib	5	1.1	1.1
Minoxidil	11	1.1	1.1
Minoxidil Foam 5% (Womens)	8	1.1	1.1
Enzalutamide	13	1.0	1.0
Vigabatrin	3	0.9	0.9
Tirzepatide	33	0.9	0.9
Cinacalcet Hydrochloride	5	0.5	0.5
Adapalene	4	0.1	0.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.